Immix Biopharma, Inc. announced the appointment of former Chimerix senior commercial leader Michael Grabow as Chief Commercial Officer. Michael will drive all aspects of commercialization and launch for NXC-201 in relapsed/refractory AL Amyloidosis. Michael has more than 25 years of biopharmaceutical commercialization experience.
Prior to joining Immix, Michael was Head of Commercial Operations at Chimerix, Inc., where he led Go-To-Market Strategy and Launch of orphan drug MODEYSO (dordaviprone), a first-in-disease therapy that was granted accelerated approval in 2025 for H3 K27M-mutant diffuse midline glioma, an ultra-rare and aggressive brain tumor that, prior to MODEYSO, previously had no FDA-approved therapies. MODEYSO was granted accelerated approval based on an integrated efficacy analysis of 50 patients, selected from five open-label studies (Jazz Pharmaceuticals acquired Chimerix for $935 million shortly after Chimerixs New Drug Application for MODEYSO was accepted and granted Priority Review by the FDA). Prior to Chimerix, Michael was Executive Vice President and Chief Business Officer of Spectrum Pharmaceuticals (SPPI, acquired by Assertio).
Prior to Spectrum, Michael held various roles at Amgen in sales and marketing. Michael has been directly involved in driving over 10 successful commercial drug launches throughout his career. Michael holds an MBA from Pepperdine University and a BS from California State University.
